Performance and Safety of a Reflux-Control Microcatheter Used to Perform DEB-TACE with LUMI Beads in HCC Patients: Preliminary Experience.

Clicks: 121
ID: 279185
2023
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #240 of 253 articles by views in journal of clinical medicine

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 253 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
The present study aims to evaluate the effectiveness and safety of the anti-reflux microcatheter during DEB-TACE with DC Bead LUMI (radiopaque beads) for the treatment of hepatocellular carcinoma (HCC).We performed an observational longitudinal prospective monocentric study to analyze all patients with HCC who underwent to DEB-TACE with DC Bead LUMI and anti-reflux microcatheter. Technical success, the presence of residual disease, and clinical success were evaluated. The performance of the anti-reflux microcatheter on the basis of the percentage of tumor covered and the non-target embolization (NTE) was also evaluated.Twenty patients underwent DEB-TACE with DC Bead LUMI and an anti-reflux microcatheter. Technical success was achieved in all cases. Residual disease in the target tumor was observed in 11/20 (55%) of cases and no residual disease was found in 9/20 (45%) of cases. The clinical response at 1-month follow-up was of PD 4/20 (20%), SD 7/20 (35%), and CR 9/20 (45%). No major complications were recorded, and 10% of cases had minor complications. The distribution of beads on post-procedural CBCT, classified according to the percentage of target nodule coverage, was ≥50% in 70% (14/20) of cases and between 30-50% in 30% of cases (6/20). NTE was never registered.
Reference Key
angileri2023performancejournal Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Angileri, Salvatore Alessio;Lanza, Carolina;Carriero, Serena;Biondetti, Pierpaolo;Ascenti, Velio;Pellegrino, Giuseppe;Caruso, Alessandro;Carrafiello, Gianpaolo;Ierardi, Anna Maria;
Journal journal of clinical medicine
Year 2023
DOI
6630
URL
Keywords
hepatocellular carcinoma (hcc) deb-tace anti-reflux microcatheter radiopaque microspheres the non-target embolization (nte)

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.